See more : Tyson Foods, Inc. (0LHR.L) Income Statement Analysis – Financial Results
Complete financial analysis of AIkido Pharma Inc. (AIKI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AIkido Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Betterware de México, S.A.P.I. de C.V. (BWMX) Income Statement Analysis – Financial Results
- AiXin Life International, Inc. (AIXN) Income Statement Analysis – Financial Results
- DyDo Group Holdings, Inc. (2590.T) Income Statement Analysis – Financial Results
- Defence Therapeutics Inc. (DTCFF) Income Statement Analysis – Financial Results
- Sasken Technologies Limited (SASKEN.NS) Income Statement Analysis – Financial Results
AIkido Pharma Inc. (AIKI)
About AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 9.00K | 28.00K | 1.24M | 877.00K | 33.00K | 10.00K | 27.00K | 19.92K | 820.93K | 1.43M | 1.36M | 1.03M | 154.70K | 24.84M | 23.05M | 22.35M | 18.09M | 15.13M | 19.94M | 17.03M | 12.70M | 16.00M | 13.60M | 13.80M | 13.70M | 16.00M | 13.60M | 16.70M | 15.10M | 15.90M | 15.30M | 13.60M | 10.50M | 8.00M | 6.70M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 81.00K | 92.00K | 84.00K | 88.00K | 864.00K | 3.00K | 0.00 | 388.07K | 517.68K | 449.29K | 397.65K | 54.29K | 20.79M | 17.93M | 17.36M | 12.60M | 11.55M | 13.64M | 11.09M | 9.60M | 12.50M | 9.90M | 9.60M | 9.90M | 12.90M | 10.40M | 13.20M | 12.40M | 13.30M | 12.90M | 11.10M | 7.70M | 5.90M | 5.20M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 9.00K | -53.00K | 1.14M | 793.00K | -55.00K | -854.00K | 24.00K | 19.92K | 432.86K | 914.78K | 909.82K | 628.32K | 100.41K | 4.04M | 5.12M | 4.99M | 5.48M | 3.58M | 6.30M | 5.95M | 3.10M | 3.50M | 3.70M | 4.20M | 3.80M | 3.10M | 3.20M | 3.50M | 2.70M | 2.60M | 2.40M | 2.50M | 2.80M | 2.10M | 1.50M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | -189.29% | 92.56% | 90.42% | -166.67% | -8,540.00% | 88.89% | 100.00% | 52.73% | 63.86% | 66.94% | 61.24% | 64.90% | 16.28% | 22.21% | 22.31% | 30.32% | 23.66% | 31.59% | 34.91% | 24.41% | 21.88% | 27.21% | 30.43% | 27.74% | 19.38% | 23.53% | 20.96% | 17.88% | 16.35% | 15.69% | 18.38% | 26.67% | 26.25% | 22.39% |
| Research & Development | 830.00K | 559.00K | 2.49M | 2.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 727.09K | 1.65M | 4.85M | 6.83M | 4.00M | 5.87M | 883.61K | 288.11K | 196.36K | 423.17K | 476.00K | 390.16K | 281.08K | 300.00K | 400.00K | 600.00K | 600.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.68M | 7.73M | 4.06M | 0.00 | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.68M | 7.73M | 4.06M | 3.17M | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 2.76M | 3.13M | 4.08M | 3.27M | 3.14M | 3.87M | 5.64M | 5.14M | 5.36M | 5.83M | 4.51M | 4.03M | 3.94M | 3.70M | 3.80M | 2.80M | 2.50M | 2.30M | 2.70M | 2.00M | 1.90M | 2.10M | 2.30M | 2.30M | 1.60M | 1.30M | 1.20M | 1.10M |
| Other Expenses | 1.83M | 1.15M | 1.47M | 0.00 | 1.44M | 1.37M | 2.14M | 6.32M | 9.83M | 291.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| Operating Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 4.78M | 8.93M | 10.10M | 7.14M | 9.74M | 6.52M | 8.00M | 7.83M | 7.76M | 6.58M | 5.84M | 5.54M | 5.70M | 5.50M | 4.00M | 3.80M | 3.30M | 3.10M | 2.50M | 2.50M | 2.70M | 2.90M | 2.80M | 2.10M | 1.70M | 1.50M | 1.30M |
| Cost & Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 5.17M | 9.44M | 10.55M | 7.54M | 9.79M | 27.32M | 25.93M | 25.19M | 20.36M | 18.13M | 19.48M | 16.62M | 15.30M | 18.00M | 13.90M | 13.40M | 13.20M | 16.00M | 12.90M | 15.70M | 15.10M | 16.20M | 15.70M | 13.20M | 9.40M | 7.40M | 6.50M |
| Interest Income | 687.00K | 252.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.46K | 6.11K | 37.65K | 348.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.76M | -2.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00K | 2.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -188.00K | 2.27M | -5.79M | 1.50M | 1.44M | 1.38M | 2.14M | 6.32M | 9.83M | 291.00K | 63.68K | 69.83K | 77.87K | 84.38K | 85.72K | 210.42K | 2.60M | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| EBITDA | -14.35M | -7.17M | -12.34M | -4.18M | 3.17M | -1.93M | -4.34M | -45.15M | -20.70M | -17.67M | -3.79M | -3.38M | -7.79M | -9.06M | -4.60M | -4.14M | 6.22M | -274.50K | -544.36K | -753.77K | -1.33M | 1.99M | 1.91M | -3.20M | -800.00K | 400.00K | 900.00K | 1.00M | 400.00K | -100.00K | 1.70M | 800.00K | 300.00K | 100.00K | 800.00K | 1.30M | 800.00K | 300.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 11,321.43% | -156.15% | -494.64% | -136,809.09% | -207,010.00% | -65,459.26% | -19,041.00% | -411.41% | -543.93% | -666.93% | -448.40% | -2,673.58% | 25.04% | -1.19% | -2.44% | -4.17% | -8.78% | 9.99% | 11.19% | -25.20% | -5.00% | 2.94% | 6.52% | 7.30% | 2.50% | -0.74% | 10.18% | 5.30% | 1.89% | 0.65% | 5.88% | 12.38% | 10.00% | 4.48% |
| Operating Income | -14.35M | -9.44M | -6.55M | -5.69M | -6.87M | -3.82M | -8.55M | -52.01M | -30.61M | -15.35M | -3.47M | -4.35M | -8.01M | -9.19M | -6.51M | -9.64M | -2.48M | -2.89M | -2.85M | -2.27M | -3.00M | 453.77K | 411.05K | -2.60M | -2.00M | -300.00K | 400.00K | 500.00K | 0.00 | 700.00K | 1.00M | 200.00K | -300.00K | -400.00K | 400.00K | 1.10M | 600.00K | 200.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -63,166.67% | -24,550.00% | -309.22% | -975.03% | -157,606.06% | -306,110.00% | -56,840.74% | -17,427.99% | -529.51% | -559.28% | -675.90% | -634.68% | -6,229.60% | -9.98% | -12.52% | -12.73% | -12.58% | -19.85% | 2.28% | 2.41% | -20.47% | -12.50% | -2.21% | 2.90% | 3.65% | 0.00% | 5.15% | 5.99% | 1.32% | -1.89% | -2.61% | 2.94% | 10.48% | 7.50% | 2.99% |
| Total Other Income/Expenses | -7.76M | 2.27M | -5.79M | 1.50M | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 899.72K | 142.02K | 37.65K | 340.23K | 377.98K | 6.10M | 37.15K | 23.45K | 17.88K | 81.07K | 114.06K | 0.00 | -2.30M | -100.00K | 100.00K | -200.00K | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | -300.00K | -100.00K | -100.00K | -200.00K | -100.00K | 0.00 |
| Income Before Tax | -22.11M | -7.17M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -2.89M | -3.45M | -7.87M | -9.15M | -6.17M | -9.26M | 3.62M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 0.00 | -4.90M | -2.10M | -200.00K | 200.00K | 500.00K | 0.00 | 600.00K | 1.10M | 200.00K | -600.00K | -500.00K | 300.00K | 900.00K | 500.00K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -14,496.70% | -419.91% | -549.37% | -673.13% | -601.52% | -5,985.26% | 14.57% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 0.00% | -38.58% | -13.13% | -1.47% | 1.45% | 3.65% | 0.00% | 4.41% | 6.59% | 1.32% | -3.77% | -3.27% | 2.21% | 8.57% | 6.25% | 0.00% |
| Income Tax Expense | 7.76M | -2.27M | 0.00 | 0.00 | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 14.49K | -133.19K | 37.65K | -552.80K | -3.41M | 105.05K | 37.15K | 23.45K | 17.88K | 81.12K | 114.06K | 0.00 | 300.00K | -100.00K | -100.00K | 100.00K | 100.00K | 100.00K | 200.00K | 400.00K | 100.00K | -200.00K | -200.00K | 100.00K | 400.00K | 200.00K | 0.00 |
| Net Income | -29.87M | -4.90M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -3.86M | -3.46M | -7.74M | -9.15M | -4.14M | -938.37K | 3.51M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 591.07K | -5.20M | -2.00M | -100.00K | 100.00K | 400.00K | -100.00K | -800.00K | 700.00K | 100.00K | -400.00K | -300.00K | 200.00K | 500.00K | 300.00K | 100.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -19,360.63% | -421.68% | -540.07% | -673.13% | -403.09% | -606.58% | 14.14% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 3.47% | -40.94% | -12.50% | -0.74% | 0.72% | 2.92% | -0.63% | -5.88% | 4.19% | 0.66% | -2.52% | -1.96% | 1.47% | 4.76% | 3.75% | 1.49% |
| EPS | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -126.45 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| EPS Diluted | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -121.90 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| Weighted Avg Shares Out | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 51.21K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
| Weighted Avg Shares Out (Dil) | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 53.13K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
AIkido Pharma (AIKI) stock is skyrocketing on Tuesday but it's not due to any positive news from the biotechnology company. The post Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
Aikido Pharma (AIKI) Stock Price: 1-For-17 Reverse Split Goes Into Effect
A 1 for 17 reverse stock split of AIkido Pharma, Inc. (NASDAQ: AIKI) has gone into effect. These are the details.
Trending Penny Stocks to Watch After Holiday Season
Which penny stocks are you watching right now? The post Trending Penny Stocks to Watch After Holiday Season appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes
There are so many traders looking for the best penny stocks 2021… The post 5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks to Buy Right Now? 3 to Watch This Month
If you're making a penny stocks watchlist in November, here's three you should check out The post Best Penny Stocks to Buy Right Now? 3 to Watch This Month appeared first on Penny Stocks to Buy, Picks, News and Information...
Best Penny Stocks to Buy in November? 3 You Need to Know About
Are these penny stocks on your November watchlist? The post Best Penny Stocks to Buy in November?
Trump-Linked SPAC Has Traders Also Focused On These 6 Stocks
The second half of October has been one of the most active periods for the stock market in quite some time. Not only did the major indexes, including the SPDR S&P 500 ETF (NYSE: SPY) and SPDR Dow Jones Industrial...
5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets
Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AIkido Pharma Trading 30% Below Cash Value Despite Positive Indications
Photo by Joshua Mayo on Unsplash Biotechnology development company AIkido Pharma Inc. (NASDAQ: AIKI) recently released its 1st-quarter report, which revealed the strongest balance sheet in the company's history with approximately $102 million in cash and cash equivalents.
Top Penny Stocks to Watch As October Gets Off to a Bullish Start
October is getting off to a great start for penny stocks, here's three to watch The post Top Penny Stocks to Watch As October Gets Off to a Bullish Start appeared first on Penny Stocks to Buy, Picks, News and...
Source: https://incomestatements.info
Category: Stock Reports